Amdocs Sees Unusually High Options Volume (NASDAQ:DOX)

Amdocs logo with Technology background
Image from MarketBeat Media, LLC.

Key Points

  • Options trading surged: Traders bought 2,152 Amdocs call options, about 430% above the average daily volume of 406; the activity may indicate bullish positioning but does not confirm a lasting change in expectations.
  • Business and legal risks weigh on the stock: Disappointing fiscal 2027 guidance linked to an escalating T-Mobile dispute preceded a roughly 30% one-day decline. Law firms have also opened investigations into potential securities claims; these are allegations, not findings of wrongdoing.
  • Analyst views are mixed: Amdocs has a consensus “Hold” rating and a $69 target price, while two directors recently bought shares totaling $142,430.
  • MarketBeat previews top five stocks to own in December.

Amdocs Limited (NASDAQ:DOX - Get Free Report) was the target of unusually large options trading on Friday. Traders bought 2,152 call options on the stock. This represents an increase of approximately 430% compared to the average daily volume of 406 call options.

Key Stories Impacting Amdocs

Investors following DOX have been watching these stories:

  • Neutral Sentiment: Call-option trading was unusually active, with 2,152 calls purchased versus an average of 406. This may reflect bullish positioning, but options activity alone does not establish a lasting shift in investor expectations.
  • Negative Sentiment: The key overhang remains disappointing fiscal 2027 guidance tied to an escalating dispute with T-Mobile. The outlook triggered a roughly 30% one-session decline on November 4, despite quarterly earnings and revenue meeting consensus. Securities investigation notice
  • Negative Sentiment: Multiple law firms have announced investigations into potential securities claims, alleging possible misleading disclosures. These are investigations—not findings of wrongdoing—but could prolong uncertainty and add reputational risk. BFA Law investigation announcement

Insider Activity at Amdocs

In related news, Director Yvette Kanouff acquired 2,400 shares of the company's stock in a transaction on Monday, November 9th. The stock was purchased at an average cost of $42.00 per share, for a total transaction of $100,800.00. Following the completion of the purchase, the director directly owned 26,600 shares of the company's stock, valued at $1,117,200. The trade was a 9.92% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John Anthony Macdonald acquired 1,000 shares of the company's stock in a transaction on Tuesday, November 10th. The shares were bought at an average price of $41.63 per share, with a total value of $41,630.00. Following the completion of the purchase, the director directly owned 25,189 shares of the company's stock, valued at approximately $1,048,618.07. This represents a 4.13% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 3,534 shares of company stock valued at $147,966 in the last 90 days. 15.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Amdocs

Institutional investors and hedge funds have recently modified their holdings of the business. Farther Finance Advisors LLC grew its stake in shares of Amdocs by 16.4% during the third quarter. Farther Finance Advisors LLC now owns 1,292 shares of the technology company's stock worth $74,000 after purchasing an additional 182 shares during the period. Alpine Bank Wealth Management increased its stake in Amdocs by 58.2% in the third quarter. Alpine Bank Wealth Management now owns 500 shares of the technology company's stock valued at $29,000 after purchasing an additional 184 shares in the last quarter. Sequoia Financial Advisors LLC raised its holdings in Amdocs by 3.5% in the first quarter. Sequoia Financial Advisors LLC now owns 6,443 shares of the technology company's stock worth $420,000 after purchasing an additional 218 shares during the period. Covestor Ltd raised its holdings in Amdocs by 11.8% in the third quarter. Covestor Ltd now owns 2,461 shares of the technology company's stock worth $141,000 after purchasing an additional 259 shares during the period. Finally, Global Retirement Partners LLC boosted its position in shares of Amdocs by 16.8% during the third quarter. Global Retirement Partners LLC now owns 2,007 shares of the technology company's stock worth $115,000 after purchasing an additional 289 shares in the last quarter. 92.02% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on DOX shares. Zacks Research downgraded shares of Amdocs from a "hold" rating to a "strong sell" rating in a report on Monday. Weiss Ratings raised shares of Amdocs from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Friday, October 23rd. Stifel Nicolaus dropped their price objective on shares of Amdocs from $71.00 to $46.00 and set a "buy" rating for the company in a report on Wednesday, November 4th. Wall Street Zen downgraded Amdocs from a "buy" rating to a "hold" rating in a report on Saturday, November 7th. Finally, Oppenheimer downgraded Amdocs from an "outperform" rating to a "market perform" rating in a report on Wednesday, November 4th. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $69.00.

View Our Latest Research Report on DOX

Amdocs Trading Up 0.9%

Shares of NASDAQ DOX traded up $0.39 during midday trading on Friday, hitting $44.50. The stock had a trading volume of 531,811 shares, compared to its average volume of 1,318,326. The company's 50-day simple moving average is $57.88 and its 200 day simple moving average is $61.17. The firm has a market cap of $4.80 billion, a P/E ratio of 9.53, a price-to-earnings-growth ratio of 1.40 and a beta of 0.42. Amdocs has a fifty-two week low of $39.96 and a fifty-two week high of $84.95. The company has a debt-to-equity ratio of 0.23, a current ratio of 0.94 and a quick ratio of 0.94.

Amdocs (NASDAQ:DOX - Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The technology company reported $1.98 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.98. The business had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.19 billion. Amdocs had a return on equity of 20.81% and a net margin of 10.59%. The firm's quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter last year, the business earned $1.83 earnings per share. Research analysts anticipate that Amdocs will post 5.82 EPS for the current year.

Amdocs Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 29th. Stockholders of record on Thursday, December 31st will be paid a $0.5690 dividend. This represents a $2.28 annualized dividend and a dividend yield of 5.1%. The ex-dividend date of this dividend is Thursday, December 31st. Amdocs's dividend payout ratio (DPR) is 48.82%.

Amdocs Company Profile

(Get Free Report)

Amdocs provides software and services to communications and media companies. Its offerings include business and operational support systems for billing, customer management, service delivery and network operations, as well as cloud and digital solutions that help clients modernize their businesses and improve customer experiences. Founded in 1982, Amdocs serves communications and media providers in markets around the world. The company is headquartered in the St. Louis, Missouri, area and is led by President and Chief Executive Officer Shuky Sheffer.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Amdocs Right Now?

Before you consider Amdocs, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amdocs wasn't on the list.

While Amdocs currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines